Loading...
Two phase III trials have shown that patients with pT3 prostate cancer achieved clinical benefit from adjuvant radiotherapy versus a wait-and-see approach after radical prostatectomy (EORTC 22911; Lancet 2005; 366:572) and SWOG 8794; J Clin Oncol 2007; 25:2225). However, advocates of salvage radiotherapy in this setting note that these trials did not prospectively test whether patients with undetectable prostate-specific antigen (PSA) levels after surgery benefited to the same degree as the entire study populations.
To address this issue, German investigators conducted a randomized study of adjuvant radiotherapy versus observation in men with pT3–T4 prostate cancers who had undetectable postoperative PSA values. Of 268 evaluable patients, 11…